Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung ca...

Full description

Bibliographic Details
Main Authors:	Xiaofeng Chen, Quan Zhu, Yiqian Liu, Ping Liu, Yongmei Yin, Renhua Guo, Kaihua Lu, Yanhong Gu, Lianke Liu, Jinghua Wang, Zhaoxia Wang, Oluf Dimitri Røe, Yongqian Shu, Lingjun Zhu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4023939?pdf=render

Similar Items

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
by: Xiaofeng Chen, et al.
Published: (2013-01-01)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
by: Xu J, et al.
Published: (2017-10-01)

Efficacy of icotinib in advanced lung squamous cell carcinoma
by: Shuai Liang, et al.
Published: (2018-09-01)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
by: Xu J, et al.
Published: (2016-05-01)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
by: Zhu L, et al.
Published: (2020-11-01)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma [Corrigendum]
by: Xu J, et al.
Published: (2017-03-01)

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)
by: Yuankai SHI, et al.
Published: (2015-07-01)

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)
by: Yuankai SHI, et al.
Published: (2016-07-01)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
by: Zhang Y, et al.
Published: (2015-06-01)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
by: Tianze Liu, et al.
Published: (2019-04-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
by: Ye CY, et al.
Published: (2016-10-01)

Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
by: He W, et al.
Published: (2016-07-01)

Democratic and ethical problem of lung cancer screening: exclusion of true high-risk populations. Can it be fixed? Yes
by: Oluf Dimitri Røe
Published: (2020-05-01)

Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride
by: Jingying NONG, et al.
Published: (2013-05-01)

Efficacy of Icotinib Hydrochloride in the Treatment of Advanced Non-small Cell Lung Cancer
by: Xianglei Ma, et al.
Published: (2013-09-01)

Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Xi LI, et al.
Published: (2015-12-01)

Clinical Analysis of Icotinib on Beneficiary of  Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
by: Xiaowen JIANG, et al.
Published: (2016-04-01)

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
by: Liang JL, et al.
Published: (2014-05-01)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
by: Shen YW, et al.
Published: (2016-02-01)

Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes
by: Wang T, et al.
Published: (2016-03-01)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
by: Wang L, et al.
Published: (2021-03-01)

The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis
by: Wang LL, et al.
Published: (2018-04-01)

Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Yiping ZHANG, et al.
Published: (2013-03-01)

Rosacea-Like Dermatitis Caused by Icotinib Hydrochloride: A Case Report
by: Pei-Pei Liu, et al.
Published: (2019-06-01)

Clinical Observation of Icotinib Hydrochloride in First-line Therapy  for Pulmonary Adenocarcinoma
by: Xinjie YANG, et al.
Published: (2013-07-01)

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
by: Zhansheng Jiang, et al.
Published: (2021-09-01)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
by: Siyang Feng, et al.
Published: (2015-01-01)

Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells
by: Wang X, et al.
Published: (2018-03-01)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
by: Wang H, et al.
Published: (2018-10-01)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
by: Liu YT, et al.
Published: (2020-06-01)

Comparison of the Efficacy and Safety of Icotinib with Standard Second-line  Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer
by: Shuyang YAO, et al.
Published: (2015-06-01)

Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2020-03-01)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
by: Yun Zhang, et al.
Published: (2021-05-01)

Combination of icotinib, surgery, and internal-radiotherapy of a patient with lung cancer severely metastasized to the vertebrae bones with EGFR mutation: a case report
by: Qu LL, et al.
Published: (2015-06-01)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
by: Long-fei Mao, et al.
Published: (2020-09-01)

Icotinib versus Cisplatin Plus Docetaxel as Adjuvant Chemotherapy in Patients with Stage II (N1+) Non-Small Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study
by: Pan S, et al.
Published: (2021-02-01)

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
by: Lei Lei, et al.
Published: (2020-01-01)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
by: Junhui Wang, et al.
Published: (2019-02-01)

Hidden treasures in ancient microarrays: Gene expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue
by: Konstantinos eKerkentzes, et al.
Published: (2014-09-01)